Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127213901 | 12721390 | 1 | I | 20160826 | 20160907 | 20160907 | EXP | JP-PFIZER INC-2016418004 | PFIZER | FUNATSU, Y.. INTIMAL SARCOMA OF THE PULMONARY ARTERY TREATED WITH PAZOPANIB. INTERNAL MEDICINE. 2016;55:16:2197-2202 | 71.00 | YR | M | Y | 0.00000 | 20160907 | MD | JP | JP |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127213901 | 12721390 | 1 | PS | Doxorubicin | DOXORUBICIN | 1 | 25 MG/ML, CYCLIC (ON DAYS 1-3, EVERY 3 WEEKS) | 50467 | |||||||||||
| 127213901 | 12721390 | 2 | SS | IFOSFAMIDE. | IFOSFAMIDE | 1 | 2.5 G/M2, CYCLIC (ON DAYS 1-4, EVERY 3 WEEKS) | 0 | 2500 | MG/M**2 | |||||||||
| 127213901 | 12721390 | 3 | SS | PAZOPANIB | PAZOPANIB | 1 | 800 MG, DAILY | U | 0 | 800 | MG |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127213901 | 12721390 | 1 | Sarcoma |
| 127213901 | 12721390 | 2 | Sarcoma |
| 127213901 | 12721390 | 3 | Sarcoma |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 127213901 | 12721390 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127213901 | 12721390 | Fatigue | |
| 127213901 | 12721390 | Neutropenia | |
| 127213901 | 12721390 | Pulmonary necrosis |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |